Cover
Cover | Nov. 16, 2023 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A (this “Amendment”) is being filed by the Company to amend the Current Report on Form 8-K (the “Prior 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2023, in connection with the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entering into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”), pursuant to which the Company acquired a controlling interest over AIBL (the “Acquisition”). |
Document Period End Date | Nov. 16, 2023 |
Entity File Number | 001-40700 |
Entity Registrant Name | ABVC BIOPHARMA, INC. |
Entity Central Index Key | 0001173313 |
Entity Tax Identification Number | 26-0014658 |
Entity Incorporation, State or Country Code | NV |
Entity Address, Address Line One | 44370 Old Warm Springs Blvd. |
Entity Address, City or Town | Fremont |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94538 |
City Area Code | 510 |
Local Phone Number | 668-0881 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ABVC |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |